Optic neuritis (ON) is an acute inflammatory demyelinating disorder of the optic nerve, most commonly presenting as subacute, painful, unilateral vision loss in young adults (annual incidence ~6.4 per 100,000 in the US). [1] It is the most common cause of subacute optic neuropathy in young adults and is frequently associated with multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). [2-3]
1. History
- Onset and progression: Subacute monocular vision loss worsening over hours to days, typically reaching nadir within 1–2 weeks [3]
- Pain: Periocular or retro-orbital pain, often worsened by eye movement — present in ~92% of ONTT patients; 70% noted worsening with eye movement; 40% reported pain before vision loss [3]
- Color vision: Ask about color desaturation (red cap test — red objects appear washed out, pink, or orange in the affected eye) [4]
- Severity: Range from mild blurring to no light perception; ~66% have acuity 20/200 or better at nadir [3]
- Prior episodes: Recurrent ON suggests NMOSD or MOGAD [2]
- Associated neurologic symptoms: Limb weakness/numbness, bladder dysfunction, intractable nausea/vomiting (area postrema syndrome in NMOSD), Lhermitte's sign [5]
- Important negatives: Trauma, recent infection/vaccination (ADEM), toxic exposures, medication history, family history of MS or autoimmune disease
2. Alarm Features
- Bilateral simultaneous vision loss — suggests NMOSD or MOGAD, not typical MS-associated ON [2-3]
- Severe vision loss (NLP or near-NLP) with poor recovery — concerning for NMOSD [3]
- Absence of eye pain — atypical; raises concern for ischemic, compressive, or infiltrative optic neuropathy [3-4]
- Severe optic disc edema, peripapillary hemorrhages, or macular exudates — red flags against typical MS-associated ON [3]
- Absence of RAPD — should prompt reconsideration of the diagnosis [3]
- Focal neurologic deficits (myelitis, brainstem signs) — escalate urgently [4]
- Steroid-refractory or steroid-dependent vision loss — consider NMOSD, MOGAD, or non-demyelinating etiology [2]
- Childhood or late adult onset (>50 years) — atypical; consider MOGAD, NMOSD, or ischemic/compressive causes [2]
3. Medications
- First-line acute treatment: IV methylprednisolone 1 g/day × 3 days, or bioequivalent high-dose oral prednisone 1,250 mg/day × 3 days (shown to be equivalent in an RCT) [1][3]
- Optional oral taper: Prednisone 1 mg/kg/day × 11 days with 3-day taper after IV pulse [4][6]
- AVOID low-dose oral prednisone alone (1 mg/kg/day) — the ONTT showed this increased recurrence risk compared to placebo [6-7]
- Steroid-refractory cases: Plasma exchange (PLEX), especially in NMOSD [8-9]
- IVIG: Alternative when PLEX is unavailable [8]
- Long-term DMTs:
- MS: Early high-efficacy disease-modifying therapy if brain MRI shows demyelinating lesions [8]
- NMOSD: Eculizumab, satralizumab, or inebilizumab [8][10]
- MOGAD: IVIG for relapse prevention [8]
- Caution: MS therapies (e.g., interferon-beta, natalizumab) can worsen NMOSD — subtype differentiation is critical before initiating DMTs [3]
4. Diet
- No specific dietary triggers or recommendations unique to optic neuritis
- Ensure adequate vitamin D intake — low vitamin D is associated with increased MS risk and relapse
- Maintain adequate hydration during high-dose steroid therapy
- Monitor blood glucose during steroid pulse (especially in diabetics)
5. Review of Systems
- Neurologic: Limb weakness, numbness, paresthesias, gait instability, Lhermitte's sign, bladder/bowel dysfunction
- GI: Intractable nausea/vomiting/hiccups (area postrema syndrome — NMOSD) [5]
- Ophthalmologic: Photopsias (phosphenes), Uhthoff phenomenon (worsening vision with heat/exercise)
- Constitutional: Fatigue, cognitive changes
- Rheumatologic: Joint pain, rash, oral ulcers (lupus, sarcoidosis, Behçet's)
- Infectious: Recent viral illness, vaccination history (post-infectious ON, ADEM)
6. Collateral History and Family History
- Family history of MS or autoimmune disease (lupus, thyroid disease, NMOSD)
- Ethnicity: NMOSD is more common in patients of Asian or African descent; MS is more common in White populations [3]
- Prior neurologic events that may have been undiagnosed (transient numbness, weakness, visual episodes)
- Social context: Smoking (increases MS risk), occupational exposures, geographic latitude (MS prevalence increases with distance from equator)
7. Risk Factors
- Age: Typical ON peaks at 20–45 years (mean ~32 years in ONTT); NMOSD mean onset ~40 years [3]
- Sex: Female predominance — 2–3:1 for MS-associated ON; 9:1 for NMOSD [3]
- Ethnicity: White populations — higher MS risk; Asian/African descent — higher NMOSD risk [3]
- Prior demyelinating events or known MS
- Vitamin D deficiency, smoking, EBV seropositivity (MS risk factors)
- Autoimmune comorbidities (lupus, sarcoidosis)
8. Differential Diagnosis
- MS-associated optic neuritis — most common; unilateral, painful, good recovery [3]
- NMOSD-associated optic neuritis — severe, bilateral, poor recovery, longitudinally extensive optic nerve lesions [3]
- MOGAD-associated optic neuritis — prominent disc edema, bilateral, steroid-responsive but relapse-prone [2]
- Anterior ischemic optic neuropathy (AION) — painless, altitudinal field defect, disc edema with splinter hemorrhages, older patients with vascular risk factors [11]
- Giant cell arteritis (arteritic AION) — age >50, jaw claudication, scalp tenderness, elevated ESR/CRP — cannot miss [11]
- Compressive optic neuropathy — meningioma, glioma; painless progressive loss, proptosis [11]
- Optic perineuritis — older patients, central vision sparing, perineural enhancement on MRI [11]
- Sarcoidosis/lupus-related optic neuropathy
- Infectious ON (syphilis, TB, viral)
- Leber hereditary optic neuropathy — bilateral, painless, young males, mitochondrial inheritance
- Toxic/nutritional optic neuropathy — bilateral, painless, central scotomas (ethambutol, methanol, B12 deficiency)
9. Past Medical History
- Prior episodes of optic neuritis or other demyelinating events
- Known MS, NMOSD, or MOGAD
- Autoimmune conditions (lupus, sarcoidosis, thyroid disease)
- History of cancer (paraneoplastic optic neuropathy — CRMP5) [2]
- Medication use: ethambutol, linezolid, amiodarone (toxic optic neuropathy)
- Surgical history: prior eye surgery
10. Physical Exam
- Visual acuity: Snellen chart — ranges from 20/20 to NLP [3]
- RAPD (Marcus Gunn pupil): Hallmark finding — ipsilateral RAPD on swinging flashlight test; required for ONTT enrollment [3-4]
- Color vision: Red desaturation (red cap test), Ishihara plates [4]
- Visual fields: Central or cecocentral scotoma most common; variable patterns [3]
- Fundoscopy:
- Two-thirds have normal optic disc (retrobulbar neuritis) [4]
- One-third have diffuse disc swelling [4]
- Severe disc edema, hemorrhages, or exudates are atypical for MS-ON — consider MOGAD, NMOSD, or non-demyelinating causes [3]
- Full neurologic exam: Assess for other demyelinating signs (pyramidal, cerebellar, sensory, bladder)
- Vital signs: Generally normal; check for hypertension (malignant hypertensive optic neuropathy)
11. Lab Studies
- Serology (send in all cases with atypical features):
- AQP4-IgG (cell-based assay preferred; >80% sensitivity, >99% specificity for NMOSD) [5]
- MOG-IgG (cell-based assay) [2][12]
- Routine labs: CBC, CMP, ESR, CRP
- If GCA suspected (age >50): ESR, CRP — urgently; temporal artery biopsy if high suspicion
- Additional as indicated: ANA, ACE level (sarcoidosis), RPR/FTA-ABS (syphilis), B12/folate, TSH
- CSF analysis (if diagnostic uncertainty): Oligoclonal bands (present in 80–90% of MS vs ~23% of NMOSD), cell count, protein, cytology [13]
- Expected findings in typical ON: Labs often normal; OCBs in CSF support MS diagnosis
12. Imaging
- First-line: MRI brain and orbits with gadolinium [3][11]
- Acute ON: T2 signal change, edema, and gadolinium enhancement of the affected optic nerve [3]
- Brain MRI is critical for MS risk stratification — 72% of patients with ≥1 white matter lesion developed MS at 15-year follow-up vs. much lower risk with normal MRI [3]
- MRI patterns by subtype: [3][11]
- MS: Short-segment, unilateral, anterior optic nerve enhancement
- NMOSD: Longitudinally extensive optic nerve lesions, chiasmal/optic tract involvement
- MOGAD: Longitudinal intraorbital lesions, perineural/orbital fat enhancement
- MRI spine: Consider if myelitis symptoms present or NMOSD suspected [13]
- CT is not adequate for optic nerve evaluation — MRI is the gold standard
- Imaging may be unnecessary in a classic first episode of typical unilateral painful ON in a young adult if clinical diagnosis is clear, but brain MRI is still recommended for prognostication [4]
The ACR Appropriateness Criteria rate MRI of the orbits with and without contrast as "usually appropriate" for suspected optic nerve pathology. [11]
13. Special Tests
- Visual evoked potentials (VEPs): Prolonged P100 latency supports optic nerve demyelination; useful for confirming subclinical ON but does not differentiate subtypes acutely [3]
- Optical coherence tomography (OCT): Measures peripapillary retinal nerve fiber layer (pRNFL) thickness; may be normal or increased acutely; chronic thinning indicates axonal loss; useful for monitoring [3][7]
- Red cap desaturation test: Quick bedside screen for dyschromatopsia [4]
- Contrast sensitivity testing: Decreased in almost all patients; may persist despite VA recovery [3]
- Humphrey visual field testing: Documents scotoma pattern and monitors recovery
14. ECG
- Not routinely indicated for optic neuritis itself
- Consider ECG if initiating fingolimod or other DMTs with cardiac effects (bradycardia risk)
- Obtain ECG if considering high-dose IV steroids in patients with cardiac history (risk of arrhythmia with rapid infusion)
15. Assessment
Optic neuritis is a clinical diagnosis based on the triad of visual loss, periocular pain, and dyschromatopsia with an ipsilateral RAPD. [13] The critical clinical task is distinguishing typical ON (idiopathic/MS-associated, generally good prognosis) from atypical ON (NMOSD, MOGAD — different prognosis and treatment). [2]
- Typical ON (MS/idiopathic): Unilateral, painful, subacute; >90% recover to 20/40 or better at 1 year; 50% develop MS at 15 years [3]
- NMOSD-associated ON: Severe vision loss, poor recovery (30% with final VA ≤20/200), high relapse rate, risk of legal blindness [3][7]
- MOGAD-associated ON: Prominent disc edema, bilateral, steroid-responsive, relapse-prone but generally better recovery than NMOSD [2][8]
Complications include permanent visual impairment, recurrent attacks, and progression to MS or other demyelinating disease.
16. Treatment Plan
Acute management
- High-dose corticosteroids (hastens recovery but does not change final visual outcome in typical ON): [3][6]
- IV methylprednisolone 1 g/day × 3 days, OR
- High-dose oral prednisone 1,250 mg/day × 3 days (bioequivalent alternative) [1]
- Optional oral taper: prednisone 1 mg/kg/day × 11 days then 3-day taper [4]
- For atypical ON: IV methylprednisolone 1 g/day × 3–5 days followed by prolonged oral taper over 4–6 months [14]
- Steroid-refractory cases (especially NMOSD): Plasma exchange — early initiation (<48 hours) improves outcomes [8-9]
- IVIG: Alternative if PLEX unavailable [8]
Long-term management
- MS: Discuss early high-efficacy DMT if brain MRI shows demyelinating lesions [8]
- NMOSD: Immediate maintenance immunosuppression — eculizumab, satralizumab, or inebilizumab [8][10]
- MOGAD: IVIG for relapse prevention; prolonged steroid taper for initial episode [8][14]
The following figure from the landmark ONTT demonstrates that IV methylprednisolone accelerated visual recovery compared to placebo and oral prednisone across all visual function measures:
17. Disposition
- Admit if:
- Severe bilateral vision loss or NLP vision
- Suspected NMOSD requiring IV steroids + PLEX
- Concurrent myelitis or other acute neurologic deficits
- Unable to tolerate oral medications or requires IV steroid infusion
- Observation/infusion center: Mild-moderate typical ON receiving IV methylprednisolone (can often be managed as outpatient infusion over 3 days)
- Discharge with outpatient follow-up if:
- Mild typical unilateral ON with preserved functional vision
- Able to take high-dose oral steroids
- Reliable follow-up with ophthalmology and/or neurology within 1–2 weeks
- Consult triggers:
- Ophthalmology: All cases for formal visual assessment
- Neurology: All cases — especially if atypical features, MRI lesions, or suspected NMOSD/MOGAD [4]
- Neuro-ophthalmology: Preferred if available
18. Follow Up / Return Precautions
- Follow-up timing: Ophthalmology/neurology within 1–2 weeks to assess recovery trajectory; if atypical features develop or recovery does not begin, immediately pursue atypical workup [14]
- Expected recovery: Vision typically begins improving within 2–4 weeks; most recovery occurs within 6 months; >90% achieve 20/40 or better at 1 year for typical ON [1][3]
- Return immediately for:
- Worsening or new vision loss in either eye
- New neurologic symptoms (weakness, numbness, gait difficulty, bladder dysfunction)
- Intractable nausea/vomiting (area postrema syndrome)
- Severe headache or eye pain not improving
- Patient counseling:
- Uhthoff phenomenon (transient worsening of vision with heat/exercise) is common and benign
- Discuss MS risk: 50% at 15 years overall; 72% if brain MRI shows white matter lesions [3]
- Importance of completing steroid course and not self-tapering
- Avoid low-dose oral prednisone monotherapy [7]
References
1. Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial. — Morrow SA, Fraser JA, Day C, et al. JAMA Neurology. 2018.
2. An Update on Optic Neuritis. — Kraker JA, Chen JJ. Journal of Neurology. 2023.
3. Optic Neuritis and Autoimmune Optic Neuropathies: Advances in Diagnosis and Treatment. — Bennett JL, Costello F, Chen JJ, et al. The Lancet. Neurology. 2023.
4. Sudden Vision Loss: A Diagnostic Approach. — Fraser JA, Son M, Vinokurtseva A. American Family Physician. 2025.
5. Neuromyelitis Optica Spectrum Disorder. — Wingerchuk DM, Lucchinetti CF. The New England Journal of Medicine. 2022.
6. Optic Neuritis. — Balcer LJ. The New England Journal of Medicine. 2006.
7. Diagnosis and Clinical Features of Common Optic Neuropathies. — Biousse V, Newman NJ. The Lancet. Neurology. 2016.
8. Updates on the Acute and Maintenance Management of Optic Neuritis Including Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody Disease. — Alchaki AR. Neurologic Clinics. 2026.
9. Evidence-Based Management of Optic Neuritis. — Bergeron E, Bouffard MA. Current Opinion in Ophthalmology. 2024.
10. FDA Orange Book. — FDA Orange Book. 2026.
11. ACR Appropriateness Criteria® Vision Loss. — Expert Panel on Neurological Imaging, Friedman ER, Juliano AF, et al. Journal of the American College of Radiology : JACR. 2025.
12. Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria. — Deschamps R, Papeix C, Demortiere S, et al. Neurology. 2026.
13. ACR Appropriateness Criteria® Demyelinating Diseases. — Expert Panel on Neurologic Imaging, Kalnins A, Lewis LM, et al. Journal of the American College of Radiology : JACR. 2026.
14. Optic Neuritis. — Toosy AT, Mason DF, Miller DH. The Lancet. Neurology. 2014.
15. A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis. — Beck RW, Cleary PA, Anderson MM, et al. The New England Journal of Medicine. 1992.